Comparative Pharmacology
Head-to-head clinical analysis: AGRYLIN versus LYNAVOY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AGRYLIN versus LYNAVOY.
AGRYLIN vs LYNAVOY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.
LYNAVOY (mirdametinib) is an oral, reversible, allosteric inhibitor of MEK1 and MEK2, blocking downstream MAPK/ERK signaling pathway activation, thereby inhibiting tumor cell proliferation and survival.
Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.
LYNAVOY (vitrakvi, larotrectinib) 100 mg orally twice daily, with or without food, until disease progression or unacceptable toxicity. For patients with body surface area <1.0 m2, the recommended dose is 100 mg/m2 per dose (maximum 100 mg per dose) twice daily.
None Documented
None Documented
Terminal elimination half-life: 1.3–1.5 days (31–36 hours) in patients with ET; allows twice-daily dosing.
Terminal elimination half-life is approximately 30–40 hours, supporting once-daily dosing. Steady-state is achieved within 2–3 weeks.
Renal: 80% (primarily unchanged drug), Biliary/Fecal: 5%
Primarily via bile into feces (approximately 77% of total clearance as unchanged drug and metabolites); renal excretion accounts for about 15% (less than 1% unchanged). A small amount is excreted in urine as metabolites.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent